Drug class
Phenothiazine-related sedative-hypnotic; histamine H1 and dopamine receptor antagonist
Mechanism of action
Produces sedation primarily through central histamine H1 receptor antagonism with additional dopamine and muscarinic receptor effects. The exact mechanism in insomnia is not fully established.
General use cases
- Short-term symptomatic treatment of insomnia in countries where propiomazine products are authorised; not a treatment for chronic insomnia without assessment of underlying causes
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
